Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phenex Pharmaceuticals AG

www.phenex-pharma.com

Latest From Phenex Pharmaceuticals AG

Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC

Although GS-9674’s efficacy data don’t appear as promising as that for Intercept’s competing FXR agonist OCA, Gilead seems to be building an argument that its drug has a better combination of efficacy and safety.

Clinical Trials Liver & Hepatic

Learning From Human Cell Hijacking Masters: ENYO Pharma Takes Virus Tricks Into Drug Discovery

Emerging Company Profile: ENYO Pharma has been around for barely four years, but it is already advancing its lead programs into Phase II trials in hepatitis B and NASH, and anticipates many more uses for its virology-based platform that will go way beyond treating virus infections.

StartUps and SMEs Platform Technologies

Gilead May Have Better Takeover Targets Than Tesaro

Gilead has once more been mentioned as a prospective acquirer of Tesaro, but analysts at Datamonitor Healthcare's PharmaVitae believe that CAR-T and NASH are the areas where the company is more likely to seek buys that reduce its reliance on hepatitis C and HIV therapies.

M & A Cancer

Gilead Data Suggest Role For ACC Inhibition In NASH

With Phase II data showing its ACC inhibitor GS-0976 can significantly reduce hepatic steatosis, Gilead moves a step closer to goal of developing a proprietary combo therapy for NASH.

Liver & Hepatic Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Hepatic (Liver)
  • Immune Disorders
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Phenex Pharmaceuticals AG
  • Senior Management
  • Claus Kremoser, PhD, CEO
    Thomas Hoffmann, CFO
    Thomas Schlüter, VP, Discovery Svcs.
  • Contact Info
  • Phenex Pharmaceuticals AG
    Phone: (49) 621 671 9600
    Donnersbergweg 1
    Ludwigshafen, D-67059
    Germany
UsernamePublicRestriction

Register